ETF veteran Kevin Kelly is the force behind Kelly ETFs, which this month introduced three funds with distinctly different focuses.
JNJ has been in a longer-term uptrend but that may not be enough to keep the rally going.
Let's review the charts and indicators.
Here's how to approach this life-sciences company.
The technical signs of the maker of heart valve systems and repair products indicate its shares could strengthen.
The bulls are back in charge.
Let's look over the charts and indicators.
The technical signals of the clinical-stage biotech company don't inspire confidence at this juncture.
TherapeuticsMD and Spark Networks are beaten-down names with recent buying interest from insiders in common.
According to the charts, VEEV appears weak and prone to further declines ahead of earnings.